RECOVERY trial finds aspirin does not improve survival for patients hospitalised with COVID-19, Recovery Trial

In the study (n=14,892), there was no evidence that aspirin 150 mg daily reduced mortality vs usual care (28 day mortality of 17% for both arms). The results were consistent across all pre-specified subgroups of patients. 8 June.

Source: Current Awareness Service for Health (CASH) - June 17, 2021 Category: Consumer Health News Source Type: news